Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

BACKGROUND: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that...

Descripción completa

Detalles Bibliográficos
Autores principales: Nannini, Margherita, Nigro, Maria Concetta, Vincenzi, Bruno, Fumagalli, Elena, Grignani, Giovanni, D’Ambrosio, Lorenzo, Badalamenti, Giuseppe, Incorvaia, Lorena, Bracci, Raffaella, Gasperoni, Silvia, Saponara, Maristella, Gatto, Lidia, Indio, Valentina, Astolfi, Annalisa, Di Scioscio, Valerio, Casali, Paolo G., Tonini, Giuseppe, Aglietta, Massimo, Russo, Antonio, Biasco, Guido, Pantaleo, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808843/
https://www.ncbi.nlm.nih.gov/pubmed/29449894
http://dx.doi.org/10.1177/1758834017742627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808843/
https://www.ncbi.nlm.nih.gov/pubmed/29449894
http://dx.doi.org/10.1177/1758834017742627

Ejemplares similares